Short Interest in GeoVax Labs, Inc. (NASDAQ:GOVX) Rises By 6.5%

GeoVax Labs, Inc. (NASDAQ:GOVX) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 511,200 shares, an increase of 6.5% from the November 30th total of 479,800 shares. Based on an average daily volume of 1,640,000 shares, the short-interest ratio is presently 0.3 days.

GeoVax Labs Trading Up 1.2 %

GOVX opened at $2.47 on Thursday. GeoVax Labs has a twelve month low of $1.09 and a twelve month high of $11.18. The company has a fifty day moving average of $2.39 and a 200-day moving average of $2.81.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.38. The business had revenue of $2.79 million for the quarter, compared to analyst estimates of $1.84 million. During the same quarter in the previous year, the business posted ($4.80) earnings per share. As a group, analysts forecast that GeoVax Labs will post -4.49 EPS for the current year.

Hedge Funds Weigh In On GeoVax Labs

A hedge fund recently bought a new stake in GeoVax Labs stock. Virtu Financial LLC bought a new position in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned approximately 0.43% of GeoVax Labs as of its most recent SEC filing. Institutional investors own 6.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Alliance Global Partners began coverage on shares of GeoVax Labs in a report on Monday, November 11th. They issued a “buy” rating and a $15.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of GeoVax Labs in a report on Friday, November 15th. Finally, D. Boral Capital reissued a “buy” rating and issued a $18.00 price objective on shares of GeoVax Labs in a research note on Wednesday, December 18th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, GeoVax Labs currently has a consensus rating of “Buy” and a consensus price target of $14.20.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.